valueforme
Posted - 5 days ago
$IMTX I'm almost ready to buy. Maybe next week
zztopps
Posted - 1 week ago
$IMTX That offering @9.25 back when looks pretty savvy at this point. (Admittedly wasn't so sure then.)XBI down 14% in less than a month. Mercy!
Santa rally??
Polip
Posted - 1 week ago
$IOVA $BMS streamlines its pipeline dropping the deal with $IMTX and $IPSC. The decision follows the presentation of early human data on Immatics' T-cell receptor project, IMA401, targeting MAGE-A4/8, at the European Society for Medical Oncology (ESMO) Congress 2024. The results were not sufficiently convincing for BMS to continue the collaboration. https://endpts.com/bristol-myers-drops-cell-therapy-pacts-with-immatics-century-as-part-of-portfolio-review/
stockandsex
Posted - 1 week ago
$IMTX $6.60 to $10 in 45 days
stockandsex
Posted - 1 week ago
$IMTX easy $10 in few months
rxptgh
Posted - 1 week ago
$IMTX opening up position here this week
S_Franconi
Posted - 1 week ago
$IMTX The company has a financial runway until the second half of 2027 and has reported a significant increase in total revenue, driven by a one-time revenue from the IMA401 partnership termination. https://finance.yahoo.com/news/why-immatics-n-v-imtx-180757431.html
S_Franconi
Posted - 1 week ago
$IMTX Overall IMTX ranks 4th on our list of the best German stocks to buy. https://finance.yahoo.com/news/immatics-n-v-imtx-best-232458246.html
zztopps
Posted - 2 weeks ago
$IMTX Tax loss selling continues to ravage the sector. Low volume walk down. Focus on the fundamentals.
S_Franconi
Posted - 3 weeks ago
$IMTX
joanna1993
Posted - 1 month ago
$IMTX dip to buy, plan to see 12 again
garrettt_88
Posted - 1 month ago
$IMTX Seems like much of the upside was tied to the recent data released, which the offering held down. Any near term catalyst here?
zztopps
Posted - 1 month ago
$IMTX Tax loss selling not helping nor is pall over biopharna space. GLLs.
Thestocktraderhubzee
Posted - 1 month ago
WATCHLIST NOV 20 2024
$SYM DA Davidson Maintains Buy on Symbotic, Maintains $47 Price Target
$ATNM Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target
$IMTX B of A Securities Maintains Buy on Immatics, Lowers Price Target to $15
$FUTU Citigroup Downgrades Futu Hldgs to Neutral, Raises Price Target to $95
$AKYA Piper Sandler Reiterates Overweight on Akoya Biosciences, Lowers Price Target to $3
Ned_Nosurname
Posted - 1 month ago
$IMTX Still early, but based on the data, and the fact that BMY abandoned IMA401, it isn't a great vote of confidence in their bispecific platform.
DonCorleone77
Posted - 1 month ago
$IMTX Immatics announces clinical data on TCER IMA402 targeting PRAME Immatics is providing the first clinical data update from the ongoing Phase 1 dose escalation trial evaluating its next-generation, half-life extended TCR Bispecific molecule, TCER IMA402 targeting PRAME. Patient Population: As of the data cut-off on November 6, 2024, 33 heavily pretreated patients with recurrent and/or refractory solid tumors have been treated with a dose range from 0.02 mg to 4 mg of IMA402 monotherapy. The treated patient population is composed of patients with a median of three and a maximum of five lines of prior systemic treatments. The safety population includes all 33 patients treated with IMA402, of which 21 patients were evaluable for efficacy analysis and are PRAME-positive or were not tested for PRAME. Of these 21 patients, eight patients received at least one dose of IMA402 at dose level 7, and one patient received IMA402 at dose level 8. Based on preclinical in-vivo data, relevant anti-tumor efficacy was expected starting at ~3 mg human equivalent dose, which aligns with the initial clinical anti-tumor activity reported today. Safety: IMA402 demonstrated a favorable tolerability profile in the 33 patients treated. The most common treatment-related adverse events were mostly mild to moderate cytokine release syndrome and transient lymphopenia. Step dosing has been implemented and dose escalation is ongoing. The maximum tolerated dose has not yet been determined. Pharmacokinetics: Early pharmacokinetic data indicate a median half-life of approximately seven days, potentially enabling bi-weekly dosing. Initial Anti-Tumor Activity: Initial signs of clinical activity have been observed and are associated with PRAME expression and IMA402 dose levels administered. In the PRAME-negative patient population across all doses and indications, only one patient out of seven showed tumor shrinkage of -2.9%. In comparison, in the PRAME-positive or non-tested patients across all indications treated with low dose levels tumor shrinkage was observed in 25% of patients, including one unconfirmed partial response in a cutaneous melanoma patient. Nine patients with tumors that tested PRAME-positive or were not tested for PRAME received a relevant dose. 78% thereof experienced shrinkage of their target lesions, including several patients with significant ongoing tumor shrinkage: one cutaneous melanoma patient with an ongoing confirmed partial response with -40.2% tumor shrinkage treated at DL7; two patients with ongoing stable diseases with significant tumor shrinkage; one ovarian cancer patient with ongoing stable disease and tumor shrinkage of -13% started at DL6 and currently at DL7.
DonCorleone77
Posted - 1 month ago
$IMTX Immatics sees cash runway into 2H27 Cash and cash equivalents as well as other financial assets total $549.2M as of September 30, 2024, compared to $476.8M as of December 31, 2023. The increase is mainly due to the public offering in January 2024, partly offset by ongoing research and development activities. Following the $150M public offering in October 2024, the Company now projects a cash runway into the second half of 2027.
DonCorleone77
Posted - 1 month ago
$IMTX Immatics reports Q3 EPS (EUR 0.11) vs. (EUR 0.32) last year Reports Q3 revenue EUR 50.5M vs. EUR 5.9M last year. "This year, Immatics has demonstrated the strength of its pipeline by announcing data on clinical activity for its four clinical-stage assets across two therapeutic modalities. These include ACTengine IMA203 targeting PRAME positioned in 2L+ melanoma now moving forward into the Phase 3 trial SUPRAME targeting BLA filing in early 2027; ACTengine IMA203CD8 targeting hard-to-treat solid cancers with an initial focus on ovarian and endometrial cancers; and TCER IMA401 targeting MAGEA4/8 demonstrating clinical proof-of-concept during dose escalation and positioned in squamous NSCLC and head and neck cancer. Today, we are very pleased to announce first clinical data on TCER IMA402 targeting PRAME, which show promising signals of anti-tumor activity during early dose escalation and is initially positioned in 1L+ melanoma," said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. "With our enhanced cash runway into the second half of 2027, Immatics is well positioned to advance all four candidates to highly relevant value inflection points with a specific focus on delivering meaningful clinical signals in multiple solid cancers in the coming year."
Holdiwatmunter
Posted - 1 month ago
@howardlindzon what a pity for $IMTX too! They are genius!
justiceforb_85
Posted - 1 month ago
$IMTX reason for bearish sentiment despite promise for metastatic melanoma? https://www.onclive.com/view/ima203-displays-efficacy-in-heavily-pretreated-melanoma
dhovekamp42
Posted - 1 month ago
$IMTX TCR therapies at SITC 2024 with Immatics focus on PRAME in #melanoma vs TILs https://www.biotechtv.com/post/immatics-november-9-2024 cc $ADAP $IMCR $IOVA
S_Franconi
Posted - 1 month ago
$IMTX Extremely Impressive List of Presentations. Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 Nov 8 & 9th. 2 Oral Presentations, 5 Poster Presentations. https://investors.immatics.com/news-releases/news-release-details/immatics-announces-upcoming-oral-and-poster-presentations
aj_
Posted - 1 month ago
$IMTX $IOVA @BiotechBlues so you do stoopit, huh?
Ever see anyone suffer with metastatic melanoma? Too expensive to be used? “For every gram of tumor there are kilos of metastasis” my path anatomy professor in med school. Dope.
S_Franconi
Posted - 1 month ago
$IMTX Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME https://investors.immatics.com/news-releases/news-release-details/immatics-announces-multiple-presentations-39th-annual-meeting-0
S_Franconi
Posted - 1 month ago
$IMTX November 8, 2024 5:00 PM EST Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME https://investors.immatics.com/news-releases/news-release-details/immatics-announces-multiple-presentations-39th-annual-meeting-0
